Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia

Liang, Ying; Su, Yun-Ai; Zhao, Zhenguo; Gao, Nan; Huang, Ji-Zhong; Mao-qin, Tang; Li, Keqing; Yang, Fude; Yu, Xin; Si, Tianmei

doi:10.1097/jcp.0000000000000379

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though no previous data have been published with regard to collagen alpha-1 (II) and collagen alpha-2 (I) chains in schizophrenia, Doknic et al [44] reported that a potential long-term consequence of asymptomatic hypogonadism due to risperidone-induced hyperprolactinemia may cause a slight rise in the C-terminal telopeptide of type I collagen (CTX), particularly in patients with schizophrenia who have been treated with long-acting injectable risperidone (LAIR) for 12 to 24 months. Liang et al [45] also reported significantly increased levels of the amisulpride group in patients with schizophrenia after 4 weeks of antipsychotic treatment.…”

Section: Discussionmentioning

confidence: 99%

Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia

Liu

Luo

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:Diagnosing schizophrenia is primarily based on the presentation of defined signs and symptoms, none of which is pathognomonic for this group of syndromes. However, few significant genome-wide associations between schizophrenia and individual have detected. Protein profiling of candidate serum biomarkers in schizophrenia is therefore an area of great interest.Methods:In the present study, we used a combination of 7% polyethylene glycol (PEG) enrichment of immune complexes and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to separate abnormal band, then analyse the band with liquid chromatography mass spectrometry (LC-MS).Results:There is a special 150-kD electrophoretic band in patients with schizophrenia, bipolar disorder, or depression relative to healthy controls (each 30 samples). Analysis of the band using LC-MS resulted in the identification of 11 serum proteins whose abundance was altered between patients and controls. Among them, 8 proteins (CFH, CFB, cDNA FLJ75416, zinc finger protein 729, isoform 2 of nidogen-1, diaphanous-1, cDNA FLJ77762, and cDNA FLJ58411) were up regulated, while one protein (isoform 1 of collagen alpha-1 (II) was down regulated in patients with schizophrenia, but only zinc finger protein 729 has statistics significance (P < .05). No differences were noted with regard to thrombospondin-1 or collagen alpha-2 (I) among the 3 groups. These proteins take part in several biological functions such as focal adhesion, complement cascades, ECM-receptor interaction, and Staphylococcus aureus infection.Conclusions:The 150-kD electrophoretic band or zinc finger protein 729 may become biomarkers in patients with schizophrenia. In the future increasing sample size and function research of zinc finger protein 729 should be executed continuously.

show abstract

Section: Discussionmentioning

confidence: 99%

Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia

Liu

Luo

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Although studies have not consistently reported associations between bone mineral density (BMD) and prolactin levels in antipsychotic-treated patients (5), antipsychotic-induced hyperprolactinaemia has been suggested a causal factor underlying osteoporosis (6). BMD is commonly assessed by dual-energy X-ray absorptiometry (DXA).…”

Section: Introductionmentioning

confidence: 99%

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

et al. 2019

View full text Add to dashboard Cite

Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover.Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers (BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia spectrum disorder. Baseline BTMs were compared to sex- and age-adjusted reference values from a Danish population cohort, and T- and Z-scores were calculated for BMD.Results: In women (n = 24), all baseline BTM measurements of procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were within reference values. In men (n = 21), 5% displayed lower PINP and 14% displayed lower CTX. One patient displayed BMD Z-score < −2, and 23% of patients (17% of women and 29% of men) displayed −2.5 < T-scores < –1 indicating osteopenia, but none had osteoporosis. After treatment, PINP decreased at trend level significance (P = 0.05), and body mass index BMD increased for L2–L4 (P = 0.016). No changes in bone markers were significant after correction for mean prolactin levels.Conclusions: Sex- and age-adjusted measures of bone status in chronic, obese, antipsychotic-treated patients appeared comparable to the reference population. Subtle changes in bone markers during 3 months exenatide treatment may suggest beneficial effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and further studies should consider the potential influence of prolactin.

show abstract

Long-term second-generation antipsychotics decreases bone formation and resorption in male patients with schizophrenia

Wang,

Li,

et al. 2024

Psychopharmacology

View full text Add to dashboard Cite

Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia

Cited by 5 publications

References 17 publications

Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia

Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Long-term second-generation antipsychotics decreases bone formation and resorption in male patients with schizophrenia

Contact Info

Product

Resources

About